News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 07 - 27

Efung Glory | Riding the Cycle, Setting the Benchmark: Efung Capital Wins Dual Awards in LP CLUB's M

Recently, the results of LP CLUB's 2026 Mid-Year Rankings were officially announced!Efung Capital was honored on the prestigious China Equity Investment Outstanding Performance GP List, while Mr. Zhu Pai, CEO of Efung Capital, was named to the U45 China Equity Investment New Generation Leaders TOP50.In 2026, China's equity investment industry stands at a critical watershed of a new cycle. With the full rollout of the "15th Five-Year Plan," the deepening implementation of new quality productive forces, and technological innovation elevated to a core nationa...

浏览次数：2

查看详情>>

发布时间: 2026 - 07 - 27

"Shenzhen Moment" in Venture Capital | Efung Capital Wins Golden Eagle Award, Zhu Pai Attends the 14

Shenzhen, July 24, 2026Securities Times and the National Venture Capital Association Alliance, with a focus on the Greater Bay Area, convened the 14th Venture Capital Conference as scheduled. Themed "Seizing New APEC Openness Opportunities to Empower Capital Market Development," the event brought together regulators, leading VC firms, tech-innovation enterprises, as well as experts from listed companies, investment banking, and commercial banking. Discussions centered around the standardized development of the VC industry and the efficient integration of technology and capital.A...

浏览次数：3

查看详情>>

发布时间: 2026 - 07 - 21

A Century of Passive Immunity Rewritten — Today, by China.

July 21, 2026 — Zhuhai Trinomab Pharmaceutical Co., Ltd. (Stock Code: 688806.SH) officially debuted on the STAR Market (SSE Sci-Tech Innovation Board) at an IPO price of RMB 14.46 per share.This is far more than a Biotech's bell-ringing ceremony. It marks the first time in over a century that an original Chinese-developed antibody therapeutic has entered the capital markets to combat tetanus. It signals the closing chapter of an era — the old world of passive immunity, reliant on horse serum, burdened by allergy risks, and constrained by plasma supply, is turning a page. Notably, Trinomab ...

浏览次数：2

查看详情>>

发布时间: 2026 - 07 - 17

Efung News | China's Original "Intervention Without Implantation": Weiguang Medical's 355 nm Cold La

Recently, LightSaber, a single-use laser optical fiber catheter independently developed by Zhongke Rongguang, a subsidiary of Weiguang Medical, officially received approval for market launch from the National Medical Products Administration (NMPA) of China (Registration Certificate No.: 20263011418).The catheter is intended for use in combination with the previously approved FastErazer 355 nm cold laser atherectomy device (Registration Certificate No.: 20263011296) for the pretreatment of lower extremity atherosclerotic stenosis (including in-stent restenosis) and occlusive lesions, to facilit...

浏览次数：5

查看详情>>